{{Rsnum
|rsid=17152411
|Gene=ZRANB1
|Chromosome=10
|position=126649516
|Orientation=plus
|GMAF=0.1685
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 68.1 | 29.2 | 2.7
| HCB | 65.0 | 32.1 | 2.9
| JPT | 57.5 | 37.2 | 5.3
| YRI | 65.3 | 32.0 | 2.7
| ASW | 77.2 | 21.1 | 1.8
| CHB | 65.0 | 32.1 | 2.9
| CHD | 70.6 | 24.8 | 4.6
| GIH | 69.3 | 24.8 | 5.9
| LWK | 68.2 | 30.9 | 0.9
| MEX | 67.2 | 29.3 | 3.4
| MKK | 73.1 | 25.6 | 1.3
| TSI | 77.5 | 19.6 | 2.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17152411
|Name_s=
|Gene_s=ZRANB1
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.15, combined P value= 3.20E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470231
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17152411
|overall_frequency_n=21
|overall_frequency_d=128
|overall_frequency=0.164062
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}